<DOC>
	<DOCNO>NCT01862224</DOCNO>
	<brief_summary>The purpose study assess impact JNJ-38518168 rheumatoid arthritis ( RA ) disease-related biomarkers synovial biopsy tissue blood participant active RA despite methotrexate ( MTX ) therapy ass safety tolerability JNJ-38518168 one year .</brief_summary>
	<brief_title>A Synovial Biopsy Study JNJ-38518168 Participants With Active Rheumatoid Arthritis Despite Methotrexate Therapy</brief_title>
	<detailed_description>This randomize ( participant assign treatment chance ) , double-blind ( participant study personnel know treatment give ) , placebo-controlled ( placebo appear identical study drug , contain active ingredient ) , parallel-group ( treatment give group participant time ) study . Participants randomly assign 3:1 ratio receive either JNJ-38518168 52 week receive match placebo 12 week , follow JNJ-38518168 40 week . The total duration participation approximately 60 week participant , include screen visit follow-up visit . Safety tolerability JNJ-38518168 evaluate monitoring adverse event report participant throughout study . In addition , result clinical laboratory test , electrocardiogram , vital sign measurement , physical examination perform study monitor .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>Have rheumatoid arthritis ( RA ) least 6 month prior date signing informed consent screen Be positive either anticyclic citrullinated peptide ( antiCCP ) antibody rheumatoid factor ( RF ) serum screen Have active RA define purpose study persistent disease activity follow criterion : At least 4 swollen 4 tender joint use 66/68 joint count . At time screening , one tender swollen joint must include nonprosthetic knee biopsied ; serum Creactive protein ( CRP_ â‰¥ 0.60 mg/dL screen Have treat tolerate oral methotrexate ( MTX ) treatment dose 10 mg/week 25 mg/week inclusive , minimum 3 month prior date signing informed consent screen must stable MTX dose minimum 8 week prior date signing informed consent screen continue receive MTX dose Week 0 If use nonsteroidal antiinflammatory drug ( NSAIDs ) analgesic ( pain reliever ) regularly RA , participant must stable dose least 2 week prior first administration study agent . If use NSAIDs analgesic RA Week 0 , participant must receive NSAIDs analgesic RA least 2 week prior first administration study agent Has inflammatory disease RA Has history juvenile idiopathic arthritis ( JIA ) Has current sign symptom liver renal insufficiency cardiac , vascular , pulmonary , gastrointestinal , endocrine , neurologic , hematologic , psychiatric , metabolic disturbance severe , progressive , uncontrolled</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Active rheumatoid arthritis despite methotrexate therapy</keyword>
	<keyword>JNJ-38518168</keyword>
	<keyword>Synovial</keyword>
</DOC>